Lung Adenocarcinoma Harboring Concomitant EGFR Mutations and BRAF V600E Responds to a Combination of Osimertinib and Vemurafenib to Overcome Osimertinib Resistance

Subjects

Subjects :

Pulmonary and Respiratory Medicine
Cancer Research
Lung
business.industry
medicine.disease
BRAF V600E
medicine.anatomical_structure
Oncology
Egfr mutation
Concomitant
medicine
Cancer research
Adenocarcinoma
Osimertinib
Vemurafenib
business
Lung cancer
medicine.drug

Details

ISSN :

15257304

Volume :

22

Database :

OpenAIRE

Journal :

Clinical Lung Cancer

Accession number :

edsair.doi...........97cafb1d9b62f1f4087319d3141ac248

Full Text :

https://doi.org/10.1016/j.cllc.2020.06.008